中华老年心脑血管病杂志

[1] 孙栋，韩雨廷，吕筠，等.当代公共卫生面临的主要挑战[J].中华流行病学杂志，2024,45(1):1-10.DOI:10.3760/cma.j.cn112338-20231115-00288.

[2] Cruz-Jentoft AJ,Sayer AA.Sarcopenia[J].Lancet,2019,393(10191):2636-2646.DOI:10.1016/S0140-6736(19)31138-9.

[3] Virani SS,Alonso A,Benjamin EJ,et al.Heart disease and stroke statistics—2020 update:a report from the American Heart Association[J].Circulation,2020,141(9):e139-e596.DOI:10.1161/CIR.0000000000000757.

[4] Yuan S,Larsson SC.Epidemiology of sarcopenia:prevalence,risk factors,and consequences[J].Metabolism,2023,144:155533.DOI:10.1016/j.metabol.2023.155533.

[5] Zengin A,Kulkarni B,Khadilkar AV,et al.Prevalence of sarcopenia and relationships between muscle and bone in Indian men and women[J].Calcif Tissue Int,2021,109(4):423-433.DOI:10.1007/s00223-021-00860-1.

[6] Purcell SA,Mackenzie M,Barbosa-Silva TG,et al.Sarcopenia prevalence using different definitions in older community-dwelling Canadians[J].J Nutr Health Aging,2020,24(7):783-790.DOI:10.1007/s12603-020-1427-z.

[7] Shafiee G,Keshtkar A,Soltani A,et al.Prevalence of sarcopenia in the world:a systematic review and meta- analysis of general population studies[J].J Diabetes Metab Disord,2017,16:21.DOI:10.1186/s40200-017-0302-x.

[8] Xin C,Sun X,Lu L,et al.Prevalence of sarcopenia in older Chinese adults:a systematic review and meta-analysis[J].BMJ Open,2021,11(8):e041879.DOI:10.1136/bmjopen-2020-041879.

[9] Wu X,Li X,Xu M,et al.Sarcopenia prevalence and associated factors among older Chinese population:Findings from the China Health and Retirement Longitudinal Study[J].PLoS ONE,2021,16(3):e0247617.DOI:10.1371/journal.pone.0247617.

[10] Huang J,He F,Gu X,et al.Estimation of sarcopenia prevalence in individuals at different ages from Zhejiang province in China[J].Aging (Albany NY),2021,13(4):6066-6075.DOI:10.18632/aging.202567.

[11] Chen Z,Li WY,Ho M,et al.The prevalence of sarcopenia in Chinese older adults:Meta-analysis and Meta-regression[J].Nutrients,2021,13(5):1441.DOI:10.3390/nu13051441.

[12] Liu X,Hou L,Xia X,et al.Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment:findings from West-China health and aging trend study[J].BMC Geriatr,2020,20(1):63.DOI:10.1186/s12877-020-1468-5.

[13] Kearney PM,Whelton M,Reynolds K,et al.Global burden of hypertension:analysis of worldwide data[J].Lancet,2005,365(9455):217-223.DOI:10.1016/S0140-6736(05)17741-1.

[14] NCD Risk Factor Collaboration (NCD-RisC).Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019:a pooled analysis of 1201 population-representative studies with 104 million participants[J].Lancet,2021,398(10304):957-980.DOI:10.1016/S0140-6736(21)01330-1.

[15] Wang Z,Chen Z,Zhang L,et al.Status of hypertension in China:results from the China hypertension survey,2012—2015[J].Circulation,2018,137(22):2344-2356.DOI:10.1161/CIRCULATIONAHA.117.032380.

[16] 张梅，吴静，张笑，等.2018年中国成年居民高血压患病与控制状况研究[J].中华流行病学杂志，2021,42(10):1780-1789.DOI:10.3760/cma.j.cn112338-20210508-00379.

[17] Xing E,Wan C.Prevalence of and factors associated with sarcopenia among elderly individuals with hypertension[J].J Int Med Res,2022,50(7):03000605221110490.DOI:10.1177/03000605221110490.

[18] Han K,Park YM,Kwon HS,et al.Sarcopenia as a determinant of blood pressure in older Koreans:findings from the Korea National Health and Nutrition Examination Surveys (KNHANES) 2008—2010[J].PLoS ONE,2014,9(1):e86902.DOI:10.1371/journal.pone.0086902.

[19] 张凡，叶春艳，柳龙根，等.成年超重及肥胖人群中肌肉减少性肥胖与2型糖尿病、高血压及高脂血症相关性研究[J].实用临床医药杂志，2019,23(12):49-53.DOI:10.7619/jcmp.201912015.

[20] Bai T,Fang F,Li F,et al.Sarcopenia is associated with hypertension in older adults:a systematic review and meta-analysis[J].BMC Geriatr,2020,20(1):279.DOI:10.1186/s12877-020-01672-y.

[21] Keskin K,?ift?i S,?ncü J,et al.Orthostatic hypotension and age-related sarcopenia[J].Turk J Phys Med Rehabil,2021,67(1):25-31.DOI:10.5606/tftrd.2021.5461.

[22] Kim KI,Kang MG,Yoon SJ,et al.Relationship between within-visit blood pressure variability and skeletal muscle mass[J].J Nutr Health Aging,2019,23(1):79-83.DOI:10.1007/s12603-018-1115-4.

[23] Zhang XZ,Xie WQ,Chen L,et al.Blood flow restriction training for the intervention of sarcopenia:current stage and future perspective[J].Front Med (Lausanne),2022,9:894996.DOI:10.3389/fmed.2022.894996.

[24] Thornton M,Sim M,Kennedy MA,et al.Nutrition interventions on muscle-related components of sarcopenia in females:a systematic review of randomized controlled trials[J].Calcif Tissue Int,2024,114(1):38-52.DOI:10.1007/s00223-023-01157-1.

[25] Quan Y,Wang C,Wang L,et al.Geriatric sarcopenia is associated with hypertension:a systematic review and meta-analysis[J].J Clin Hypertens (Greenwich),2023,25(9):808-816.DOI:10.1111/jch.14714.

[26] Sieber CC.Malnutrition and sarcopenia[J].Aging Clin Exp Res,2019,31(6):793-798.DOI:10.1007/s40520-019-011 70-1.

[27] de la Guía-Galipienso F,Martínez-Ferran M,Vallecillo N,et al.Vitamin D and cardiovascular health[J].Clin Nutr,2021,40(5):2946-2957.DOI:10.1016/j.clnu.2020.12.025.

[28] De Ciuceis C,Rizzoni D,Palatini P.Microcirculation and physical exercise in hypertension[J].Hypertension,2023,80(4):730-739.DOI:10.1161/HYPERTENSIONAHA.122.19465.

[29] Tabara Y,Ikezoe T,Yamanaka M,et al.Advanced glycation end product accumulation is associated with low skeletal muscle mass,weak muscle strength,and reduced bone density:the nagahama study[J].J Gerontol A Biol Sci Med Sci,2019,74(9):1446-1453.DOI:10.1093/gerona/gly233.

[30] Jia G,Sowers JR.Hypertension in diabetes:an update of basic mechanisms and clinical disease[J].Hypertension,2021,78(5):1197-1205.DOI:10.1161/HYPERTENSIONAHA.121.17981.

[31] Li S,Wang X,Zhao L,et al.The characteristics of 24-hour ambulatory blood pressure monitoring and its relationship with cardiovascular target organ damage in Chinese Han patients with concomitant type 2 diabetes and hypertension[J].Blood Press Monit,2019,24(4):167-173.DOI:10.1097/MBP.0000000000000389.

[32] Livshits G,Kalinkovich A.Restoration of epigenetic impairment in the skeletal muscle and chronic inflammation resolution as a therapeutic approach in sarcopenia[J].Ageing Res Rev,2024,96:102267.DOI:10.1016/j.arr.2024.102267.

[33] Rivera FB,Escolano BT,Nifas FM,et al.Interrelationship of sarcopenia and cardiovascular diseases:a review of potential mechanisms and management[J].J ASEAN Fed Endocr Soc,2024,39(1):69-78.DOI:10.15605/jafes.039.01.03.

[34] Deng C,Lu C,Wang K,et al.Celecoxib ameliorates diabetic sarcopenia by inhibiting inflammation,stress response,mitochondrial dysfunction,and subsequent activation of the protein degradation systems[J].Front Pharmacol,2024,15:1344276.DOI:10.3389/fphar.2024.1344276.

[35] Franco C,Sciatti E,Favero G,et al.Essential hypertension and oxidative stress:novel future perspectives[J].Int J Mol Sci,2022,23(22):14489.DOI:10.3390/ijms232214489.

[36] Jung UJ.Sarcopenic Obesity:Involvement of oxidative stress and beneficial role of antioxidant flavonoids[J].Antioxidants (Basel),2023,12(5):1063.DOI:10.3390/antiox12051063.

[37] Cereda E,Pisati R,Rondanelli M,et al.Whey protein,leucine- and Vitamin-D-enriched oral nutritional supplementation for the treatment of sarcopenia[J].Nutrients,2022,14(7):1524.DOI:10.3390/nu14071524.